DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Competitor Analysis: Complement C5 Inhibitors 2017 - Biosuperiors & Biosimilars" report to their offering.
This Competitive Intelligence report about Complement C5 Inhibitors 2017 - Biosuperiors & Biosimilars provides a competitor evaluation in the field of mainly recombinant antibodies, but also proteins, peptides, RNA and small molecules acting as inibitors of complement C5 or antagonists of the C5a receptor as of March 2017.
With annual sales of nearly US$ 3 bln in 2016, Soliris from Alexion Pharmaceuticals has set the stage for next generation biosuperiors as well as biosimilars of a commercially successful and clinically effective treatment of complement C5 mediated diseases. New treatment modalities in development aim at improving the mode and frequency of administration as well as the scope of indications. Players in the field not only include small and medium biotech, but also Big Pharmas
The report includes a compilation of currently active projects in research and development of inhibitors of complement C5 or antagonists of the C5a recepotr. In addition, the report lists company-specific R&D pipelines of C5 inhibitors.
Competitor projects are listed in a tabular format providing information on:
- Drug Codes
- Target/Mechanism of Action
- Class of Compound
- Product Category
- R&D Stage
- Additional comments with a hyperlink leading to the source of information.
Key Topics Covered:
1. Soliris Pipeline
2. Soliris Biosimilars
3. Novel Complement C5 Inhibitors
4. Complement C5a Receptor Antagonist
5. Corporate C5 Inhibitor R&D Pipelines
For more information about this report visit https://www.researchandmarkets.com/research/rt2ztx/competitor